loading page

Being diagnosed with a rhabdomyosarcoma in the era of artificial intelligence: who can we trust?
  • +8
  • Annalisa Consoli,
  • Alice Bernasconi,
  • Paolo Lasalvia,
  • Gianni Bisogno,
  • Giuseppe Maria Milano,
  • Annalisa Trama,
  • Stefano Chiaravalli,
  • Luca Bergamaschi,
  • Michela Casanova,
  • Maura Massimino,
  • Andrea Ferrari
Annalisa Consoli
Fondazione IRCCS Istituto Nazionale dei Tumori
Author Profile
Alice Bernasconi
Fondazione IRCCS Istituto Nazionale dei Tumori

Corresponding Author:alice.bernasconi@istitutotumori.mi.it

Author Profile
Paolo Lasalvia
Fondazione IRCCS Istituto Nazionale dei Tumori
Author Profile
Gianni Bisogno
University of Padua
Author Profile
Giuseppe Maria Milano
Ospedale Pediatrico Bambino Gesu
Author Profile
Annalisa Trama
Fondazione IRCCS Istituto Nazionale dei Tumori
Author Profile
Stefano Chiaravalli
Fondazione IRCCS Istituto Nazionale dei Tumori
Author Profile
Luca Bergamaschi
Fondazione IRCCS Istituto Nazionale dei Tumori
Author Profile
Michela Casanova
Fondazione IRCCS Istituto Nazionale dei Tumori
Author Profile
Maura Massimino
Fondazione IRCCS Istituto Nazionale dei Tumori
Author Profile
Andrea Ferrari
Fondazione IRCCS Istituto Nazionale dei Tumori
Author Profile

Abstract

In the era of big data, young patients are overwhelmed by artificial intelligence-based tools, such as chatbots. Five clinical experts were asked to evaluate the performance of four of the most currently used chatbots at providing information on a rare cancer affecting young people, such as rhabdomyosarcoma. In general, despite their high performance at giving general information about the disease, these chatbots were considered by the experts inappropriate at providing suggestion on cancer treatments and specialized centers, also lacking of "sensitivity". Efforts are envisioned by the pediatric oncology community to improve the quality of data used to train these tools.
Submitted to Pediatric Blood & Cancer
04 Jun 2024Submission Checks Completed
04 Jun 2024Assigned to Editor
08 Jul 2024Review(s) Completed, Editorial Evaluation Pending
09 Jul 2024Editorial Decision: Revise Major
22 Jul 2024Submission Checks Completed
22 Jul 2024Assigned to Editor
22 Jul 20241st Revision Received
22 Jul 2024Review(s) Completed, Editorial Evaluation Pending
23 Jul 2024Reviewer(s) Assigned
26 Jul 2024Editorial Decision: Accept